| Name | Title | Contact Details |
|---|
AutoCruitment is a metrics-driven ecosystem of patient recruitment and engagement solutions, digitizing and revolutionizing the end-to-end patient and client experience. Our multifaceted approach utilizes sophisticated algorithms, advanced automation, and over 1,500 direct-to-patient online channels to find, screen, and automatically refer highly qualified patients with a greater chance of randomization success. The results are higher enrollment and greater patient engagement, accelerating timelines and exceeding milestones at every phase of clinical research. The AutoCruitment Difference: •Targeted: The AutoCruitment platform`s proprietary algorithms and innovative approach help precisely target your ideal patient population, reaching over 247 million patients to date •Experienced: AutoCruitment has completed over 578 studies and has a continuously learning and growing database of over 10 million patients •Technology-Enabled: The AutoCruitment platform utilizes advanced online screeners to simultaneously screen for multiple studies and provide customized cohort volumes based on your project`s needs •Volume- and Quality-Focused: The far-reaching power of the AutoCruitment platform and our direct-to-patient methodology excels at attracting and retaining optimal volumes of highly qualified patients •Transparent: The AutoCruitment portal and its robust reporting capabilities enable complete and real-time transparency from the very beginning •Metrics-Driven: Our patient recruitment scientists work in complete collaboration with your study teams and research sites to optimize the program and increase randomization by an average of 97% per month AutoCruitment delivers something different. Our comprehensive ecosystem of scalable solutions offers a 3-day startup time and swiftly removes the recruitment barrier for biotech innovations and pharmaceutical research, shortening timelines and trimming budgets for a quicker, smoother path to market.
Amolyt Pharma is building on its team`s established expertise in therapeutic peptides development to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases. Amolyt Pharma`s programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism. The collaborative Amolyt Pharma team is well-equipped for upcoming milestones and for the adoption of additional programs as made possible by its global network in the field of endocrinology and with support from a strong syndicate of international investors.
Ipsen S.A. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Find the most effective and affordable therapy, counseling, and treatments with Foresight! With our advanced technology, we make sure to provide the most effective and accurate treatment to our patients. We accept most insurances, so book today and sta...
Amgenix International is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.